Anti-tigit antibodies and uses thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- HISUN BIORAY PHARMA CO LTD
- Publication Date
- 2022-06-07
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biology and relates to an anti-TIGIT antibody. Background technique
[0002] Malignant tumors (cancer) are one of the major diseases that seriously affect the health of the Chinese population, and the morbidity and mortality of malignant tumors have been on the rise in recent decades. At present, the treatment methods for tumors are still surgery, radiotherapy and chemotherapy. With the deepening of the understanding of the mechanism of tumorigenesis, immunotherapy has completely changed the clinical treatment of advanced malignant tumors, and has also greatly reversed the current status of tumor treatment methods. Immunotherapy represented by immune checkpoint inhibitors such as PD-1 / PD-L1 and CTLA-4 can block immunosuppressive signals, thereby promoting the activation of T cells and the immune response to tumors. However, current immunotherapy suffers from low response rates and drug resistance, suggesting that...